Last Update 03 Feb 26

Fair value Decreased 3.00%

SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks

Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks.

Analyst Commentary

Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples. Several major firms, including JPMorgan and Barclays, have set new price objectives, and these moves feed directly into the higher average target around CHF 60 mentioned earlier.

Across the reports, analysts appear to be revisiting assumptions on earnings power and appropriate P/E levels for Sandoz relative to its peers. Some are aligning targets closer to CHF 60, while others are using higher reference points such as CHF 70, which indicates a wide range of views on what investors might be willing to pay for the shares.

For you as an investor, the key takeaway is that the current set of targets reflects different judgments on how reliably Sandoz can execute on its growth plans and sustain margins over time. JPMorgan, for example, has set a target of CHF 60 and maintained an Overweight stance, which signals confidence in the company’s longer term positioning but also implies that valuation already embeds some expectations for delivery.

Barclays has also published a target of CHF 70 with an Overweight rating, pointing to a higher price anchor than the average. That creates a spread between the more optimistic and more cautious views, and this spread is where your own risk tolerance and time horizon matter most.

Overall, the Street is not uniform. Some research focuses on the potential upside if execution stays on track, while others place more weight on possible disruptions to growth, cost controls or competitive pressures that could limit how much investors are willing to pay for the stock.

Bearish Takeaways

Bearish analysts highlight that several recent targets cluster around CHF 60, which they see as leaving less margin of safety if earnings or margins fall short of current assumptions.
Some cautious views point to the gap between higher targets such as CHF 70 and the CHF 60 level, arguing that execution risks and uncertain growth visibility could justify sticking closer to the lower end of that range.
Where price targets have been reset rather than lifted more aggressively, bearish analysts see this as a signal that valuation already reflects meaningful optimism on future P/E multiples, with limited room for disappointment.
Cautious sentiment also centers on the pace of revisions, with bearish analysts concerned that frequent target changes suggest limited conviction in long term earnings trajectories and the durability of current margin assumptions.

What’s in the News

The European Commission granted marketing authorization for Ondibta insulin glargine, a pre filled pen for diabetes treatment in adults, adolescents and children from age two. This paves the way for a planned launch by early 2027 and adds another insulin biosimilar to the Sandoz portfolio (Key Developments).
Sandoz and partner EirGenix received a complete response letter from the US FDA on the trastuzumab biosimilar BLA. The FDA cited manufacturing observations but no efficacy, safety or biosimilarity issues. Sandoz has already submitted supplemental documents for review (Key Developments).
Wyost and Jubbonti, denosumab biosimilars to Xgeva and Prolia, have launched in Europe across all approved indications in oncology related bone disease and osteoporosis, expanding Sandoz participation in a reference medicine market worth about US$6.6b (Key Developments).
Afqlir, an aflibercept biosimilar to Eylea for retinal diseases, has launched in Europe, starting in the UK with further EU rollouts planned. This follows an agreement with Regeneron that clears the path for a US launch of Enzeevu by the end of 2026 in an anti VEGF market of about US$15b (Key Developments).
TYRUKO, a natalizumab biosimilar for multiple sclerosis and Crohn’s disease, is now available to patients in the US and 14 European countries under a global commercialization deal with Polpharma Biologics. It is supported by a REMS safety program and an associated anti JCV antibody testing program with Labcorp (Key Developments).

Valuation Changes

Fair Value: revised slightly lower from CHF 44.19 to CHF 42.87 per share, indicating a modest reset in the underlying valuation anchor.
Discount Rate: kept broadly unchanged at about 3.86%, indicating no material shift in the assumed risk profile or required return.
Revenue Growth: adjusted from about 7.04% to about 7.12%, indicating a small change in the expected top line expansion.
Net Profit Margin: adjusted from about 13.71% to about 13.81%, indicating a slightly stronger outlook for profitability in the model.
Future P/E: adjusted from about 15.33x to about 15.01x, indicating a marginally lower assumed valuation multiple applied to future earnings.

Sustained pricing and regulatory pressures, along with rising legal risks, are likely to constrain revenue growth and earnings quality for Sandoz.
Increased investment and competition may erode margins and threaten the long-term viability of its traditional generics and biosimilars business model.
Accelerated biosimilars growth, innovative launches, expanded manufacturing, and global market reach position Sandoz for resilient revenue, improved margins, and competitive strength amid rising healthcare demand.

Catalysts

About Sandoz Group

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.What are the underlying business or industry changes driving this perspective?

Ongoing and rising global pressure on drug pricing, compounded by newly confirmed US tariffs on EU generics and biosimilars, is likely to further constrain Sandoz's ability to drive top-line revenue growth and will place significant downward pressure on net margins going forward.
The increasing regulatory complexity-marked by the need for intricate approvals and the potential for prolonged timelines across developed markets-is expected to slow new generic and biosimilar launches and could reduce Sandoz's pipeline velocity, threatening both future revenue growth and the realization of its much-touted pipeline value.
Sandoz's heavy investment in expanding manufacturing capacity and recent acquisitions (such as Just-Evotec Biologics) may increase the company's fixed cost base at a time when competition from low-cost Asian manufacturers is intensifying, leading to greater risk of margin erosion and net earnings volatility if price competition accelerates.
The accelerating shift in healthcare towards personalized and precision medicine represents a structural threat to traditional large-volume generics and biosimilars, potentially capping addressable market growth for Sandoz and threatening the long-term sustainability of its revenue base.
Heightened litigation and intellectual property risk in the biosimilars segment, together with the risk of failed launches or key setbacks in a limited set of blockbuster assets, could drive unpredictable, one-off legal and restructuring costs, affecting earnings quality and further widening the gap between adjusted and reported free cash flow.

Sandoz Group Earnings and Revenue Growth

Sandoz Group Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Sandoz Group compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Sandoz Group's revenue will grow by 4.5% annually over the next 3 years.
The bearish analysts assume that profit margins will increase from 2.1% today to 11.0% in 3 years time.
The bearish analysts expect earnings to reach $1.3 billion (and earnings per share of $3.08) by about September 2028, up from $227.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 17.3x on those 2028 earnings, down from 117.1x today. This future PE is lower than the current PE for the CH Pharmaceuticals industry at 30.3x.
Analysts expect the number of shares outstanding to grow by 0.3% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 3.82%, as per the Simply Wall St company report.

Sandoz Group Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The accelerating sales growth in biosimilars, successful product launches like Pyzchiva, Wyost, and Jubbonti in major markets, and a robust pipeline of 27 biosimilars targeting $200 billion in originator sales all point to strong future revenue growth and market share expansion for Sandoz Group.
Regulatory streamlining and increased acceptance of biosimilars are expected to accelerate approval times, lower development costs, and enable Sandoz to bring more products to market faster, thereby supporting margin improvement and long-term earnings growth.
Ongoing and significant investments in manufacturing modernization, capacity expansion in Slovenia, and the acquisition of Just-Evotec Biologics provide Sandoz with competitive advantages through cost control, increased operational efficiency, and vertical integration, which should result in improved net margins and cash flow generation.
The global shift towards generics and biosimilars, fueled by demand from an aging population, rising chronic diseases, and heightened pressure on healthcare costs, is poised to drive sustained volume growth for Sandoz, supporting steady increases in revenue and market resilience.
Geographic diversification and a leading presence in both Europe and international markets reduce dependency on the U.S. while opening access to high-growth patient populations, positioning Sandoz for stable revenue streams and less vulnerability to regional or regulatory shocks.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Sandoz Group is CHF38.02, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Sandoz Group's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF60.37, and the most bearish reporting a price target of just CHF38.02.
In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $12.1 billion, earnings will come to $1.3 billion, and it would be trading on a PE ratio of 17.3x, assuming you use a discount rate of 3.8%.
Given the current share price of CHF49.66, the bearish analyst price target of CHF38.02 is 30.6% lower. Despite analysts expecting the underlying buisness to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Sandoz Group?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins